Early-life RSV infection and parental allergy interact to substantially increase childhood asthma risk, supported by ...

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that the following medicines and indications have been renewed in ...

The FcRn-targeted immunotherapy market presents opportunities through innovative biologic treatments blocking FcRn-IgG interactions. This addresses high unmet needs in autoimmune diseases like ...

KYV-101 demonstrated significant efficacy in reducing MG-ADL and QMG scores in gMG patients, with rapid and sustained effects ...

New research provides evidence that the Alzheimer’s disease drug Lecanemab functions by activating a specific cleaning ...

Following the company’s fiscal second-quarter 2026 financial results, Oppenheimer reaffirmed its Outperform rating on ...

Learn more about whether Immunocore Holdings plc or Viridian Therapeutics, Inc. is a better investment based on AAII's A+ ...

Early Phase 1 monotherapy data demonstrate cytopenia-sparing safety, broad pharmacologic window, and early clinical activity in relapsed/refractory non-Hodgkin lymphoma (NHL) ...

Learn more about whether Vericel Corporation or Viridian Therapeutics, Inc. is a better investment based on AAII's A+ ...

This competitive intelligence report about CD47 and SIRP-alpha Targeted Immunotherapy provides an up-to-date competitor evaluation in the field of emerging therapy candidates in r ...

Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for serious and rare diseases, today ...